GSK Lotronex Risk Management Plan Should Not Be Altered, Cmte. Says
Executive Summary
GlaxoSmithKline's risk management program for Lotronex should not be altered until further data is collected, FDA's Drug Safety & Risk Management Advisory Committee recommended May 5